Hence, delivery of cytidine (or of a CTP precursor) could mitigate unwanted CTP deprivation–induced cell death or immunosuppression (in the case of cancer treatment) that might result from the use of therapeutic CTPS inhibitors. The gene discussed is CTPS1; the disease is cancer.